Anixa Biosciences Inc
ANIX · XNASCIK 715446fmd_1ETC214KBKHR6B7T9QX8ZSY29GManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Nov 01, 2009 to Jul 31, 2026, 65 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 1 | 0 | – | 1 | – | 0 | 0 | – |
| Cost of revenue | – | – | – | – | – | – | – | – | – | – |
| Gross profit | – | – | – | – | – | – | – | – | – | – |
| Research and development | 2 | 2 | 7 | 5 | 4 | 6 | 7 | 5 | 6 | 5 |
| Selling, general and administrative | 3 | 4 | 7 | 6 | – | – | – | – | – | – |
| Gain on sale of real estate | – | – | – | – | – | 0 | – | – | – | – |
| Operating income | (5) | (6) | (14) | (12) | (10) | (13) | (14) | (11) | (14) | (12) |
| Interest expense | 1 | 1 | – | – | – | – | – | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
| Income before taxes | (5) | (5) | (14) | (12) | – | – | – | – | – | – |
| Income tax expense | – | – | – | – | – | – | – | – | – | – |
| Net income from continuing operations | – | – | – | – | – | – | – | – | – | – |
| Net income | (5) | (5) | (14) | (12) | (10) | (13) | (14) | (10) | (13) | (11) |
| Net income to common shareholders | – | (7) | (14) | (12) | – | – | – | – | – | – |